Affimed N.V. announced the appointment of Dr. Joerg Windisch to the position of Chief Operating Officer. As COO, Dr. Windisch will provide his broad expertise in pharmaceutical regulatory affairs, quality control and project management to support the company's expanding clinical pipeline. The company also announced the addition of Dr. Bernhard Ehmer to its Supervisory Board.

Dr. Ehmer brings an extensive clinical development track record in biopharmaceuticals from both sides of the Atlantic. These appointments were approved by Affimed's shareholders at the extraordinary shareholder meeting held in Amsterdam on January 21, 2016. Dr. Windisch joins Affimed after spending 20 years at Sandoz Biopharmaceuticals most recently serving as Chief Science Officer.

Dr. Ehmer has been Chairman of the Management Board of Biotest AG since January 2015.